Our cohort only included four cases of KMT2A‐r ALL with equally high MRD levels in CD34 positive and CD34 negative, and our findings thus identify non‐KMT2A‐r CD34‐negative/predominantly negative cases as a subgroup with a very good response to induction therapy. This evidence concerns the gene CD34 and acute lymphoblastic leukemia.